Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on V419 given with Prevnar 13 and RotaTeq, focusing on safety, tolerability, and immunogenicity; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections
• Virus Diseases

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)
• RotaTeq (rotavirus vaccine, pentavalent)
• V419

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bacterial Infections, Virus Diseases | Phase 3 | Status: COMPLETED | Results posted: 2016-03-16